Summary: This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011].
These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service.
OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at email@example.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
* Delivery time in business days.Occasional delay may occur due to complexity of the constructs.
All shRNA Citations:
Citrullination regulates pluripotency and histone H1 binding to chromatin, Christophorou, MA;Castelo-Branco, G;Halley-Stott, RP;Oliveira, CS;Loos, R;Radzisheuskaya, A;Mowen, KA;Bertone, P;Silva, JC;Zernicka-Goetz, M;Nielsen, ML;Gurdon, JB;Kouzarides, T;,
Nature, Feb 2014.
[Padi4 ] Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy, Ahmad, T;Mukherjee, S;Pattnaik, B;Kumar, M;Singh, S;Kumar, M;Rehman, R;Tiwari, BK;Jha, KA;Barhanpurkar, AP;Wani, MR;Roy, SS;Mabalirajan, U;Ghosh, B;Agrawal, A;,
EMBO J., Feb 2014.
[Miro1] Vaccine-Mediated Immunotherapy Directed Against a Transcription Factor Driving the Metastatic Process, Ardiani, A;Gameiro, SR;Palena, C;Hamilton, D;Kwilas, A;King, TH;Schlom, J;Hodge, JW;,
Cancer Res., Feb 2014.
[Twist1] NFIB-Mediated Repression of the Epigenetic Factor Ezh2 Regulates Cortical Development, Piper, M;Barry, G;Harvey, TJ;McLeay, R;Smith, AG;Harris, L;Mason, S;Stringer, BW;Day, BW;Wray, NR;Gronostajski, RM;Bailey, TL;Boyd, AW;Richards, LJ;,
J. Neurosci., Feb 2014.
[Ezh2] INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) IS UPREGULATED IN THYROID CARCINOMA AND DRIVES THE DEVELOPMENT OF AN IMMUNOSUPPRESSANT TUMOR MICROENVIRONMENT, Moretti, S;Menicali, E;Voce, P;Morelli, S;Cantarelli, S;Sponziello, M;Colella, R;Fallarino, F;Orabona, C;Alunno, A;de Biase, D;Bini, V;Mameli, MG;Filetti, S;Gerli, R;Macchiarulo, A;Melillo, RM;Tallini, G;Santoro, M;Puccetti, P;Avenia, N;Puxeddu, E;,
J. Clin. Endocrinol. Metab., Feb 2014.
[IDO1] SNARE-dependent interaction of Src, EGF receptor and Î²1 integrin regulates invadopodium formation and tumour cell invasion, Williams, KC;Coppolino, MG;,
J. Cell. Sci., Feb 2014.
[ITGB1BP3] Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in the muscle injury model, Yang, Z;Nakagawa, K;Sarkar, A;Maruyama, J;Iwasa, H;Bao, Y;Ishigami-Yuasa, M;Ito, S;Kagechika, H;Hata, S;Nishina, H;Abe, S;Kitagawa, M;Hata, Y;,
Mol. Cell. Biol., Feb 2014.
[WWTR1 ] G Protein-Coupled Receptor Kinase-6 Interacts with Activator of G Protein Signaling-3 To Regulate CXCR2-Mediated Cellular Functions, Singh, V;Raghuwanshi, SK;Smith, N;Rivers, EJ;Richardson, RM;,
J. Immunol., Feb 2014.
[GPSM1] Mitochondrial Targeting of Cytochrome P450 (CYP) 1B1 and its Role in Polycyclic Aromatic Hydrocarbon-Induced Mitochondrial Dysfunction, Bansal, S;Leu, A;Gonzalez, FJ;Guengerich, FP;Roy Chowdhury, A;Anandathheerthavarada, HK;Avadhani, NG;,
J. Biol. Chem., Feb 2014.
[ADX] Ovarian Cancer Cell Heparan Sulfate 6-O-Sulfotransferases Regulate an Angiogenic Program Induced by HB-EGF/EGF Receptor Signaling, Cole, CL;Rushton, G;Jayson, GC;Avizienyte, E;,
J. Biol. Chem., Feb 2014.
* Delivery time is an estimate in business days. Occasional delays may occur due to unforeseen complexities in the preparation of your construct. International customers may expect an additional 1-2 weeks in shipping